Document Detail


Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
MedLine Citation:
PMID:  18598995     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. AIM: It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. METHODS: PubMed (including Epub) was searched in October 2006 and again in March 2007. RESULTS: The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increasing the risk of serious and latent infections. Screening for tuberculosis, HBV, opportunistic or latent infections, heart failure, and haematological, neurological and hepatological disorders must be performed before infliximab therapy. There is no definitive evidence that infliximab increases the risk of neoplasia. Mortality in infliximab-treated patients does not appear increased compared to the controls. CONCLUSIONS: Infliximab safety is similar to that of conventional immunomodulators and patients treated had similar rates of mortality, neoplasm and lymphoma as patients not treated with infliximab. Patients treated with infliximab have an increased risk of serious infections but it is not related to infliximab therapy.
Authors:
A Orlando; F Mocciaro; G Civitavecchia; D Scimeca; M Cottone
Related Documents :
21764335 - Benign infantile seizures and paroxysmal dyskinesia: a well-defined familial syndrome.
13680115 - Improved survival of critically ill cancer patients with septic shock.
12590325 - A predictive model for the management of community-acquired pneumonia.
17646725 - A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopa...
19147185 - Dysphagia due to anterior cervical hyperosteophytosis.
21254375 - Multiple target molecular monitoring of bone marrow and peripheral blood samples from p...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     Volume:  40 Suppl 2     ISSN:  1878-3562     ISO Abbreviation:  Dig Liver Dis     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-07     Completed Date:  2008-09-23     Revised Date:  2009-05-20    
Medline Journal Info:
Nlm Unique ID:  100958385     Medline TA:  Dig Liver Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  S236-46     Citation Subset:  IM    
Affiliation:
Department of Medicine, Pneumology and Nutrition Clinic, V. Cervello Hospital, University of Palermo, Palermo, Italy. ambrogiorlando@tiscali.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / administration & dosage,  adverse effects*
Clinical Trials as Topic
Drug Administration Schedule
Drug Therapy, Combination
Humans
Immunologic Factors / administration & dosage,  adverse effects*
Immunosuppressive Agents / therapeutic use
Inflammatory Bowel Diseases / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Infliximab in Crohn's disease: a look at the (not so distant) future.
Next Document:  Clinical course of ulcerative colitis.